Table 1 Model data inputs
From: The financial impact of increasing home-based high dose haemodialysis and peritoneal dialysis
Parameter | Value (range) | Data sources |
|---|---|---|
Mortality | ||
High dose HD mortality HR vs. conventional HD | 0.76 (0.57-0.95) | |
Home HD mortality HR vs. ICHD | 1.00 | Assumption |
Hospitalisations (28 day probabilities) | ||
Conventional ICHD | Year 1: 7.05% (5.29% - 8.81%) | Year 1: FHN trial [14] |
|  | Year 2+: 4.86% (3.65% - 6.08%) | Year 2+: Arora†[33] |
Conventional home HD | Year 1: 5.35% (4.01% - 6.68%) | Year 1: FHN trial [14] |
|  | Year 2+: 3.69% (2.77% - 4.61%) | Year 2+: Arora†[33] |
High dose HD at home | Year 1: 7.09% (5.32% - 8.86%) | Year 1: Rocco [16] |
|  | Year 2+: 4.89% (3.67% - 6.11%) | Year 2+:Arora†[33] |
All PD | Year 1: 6.69% (5.02% – 8.36%) | |
|  | Year 2+: 6.69% (5.02% - 8.36%) | Year 2+: Arora†[33] |
Transition probabilities (28 days) | ||
Transplant rate – all modalities | 0.007 (0.005 – 0.009) | |
Graft failure probability – all modalities | 0.004 (0.003 – 0.005) | NHS Blood and Transplant Activity Report for 2012-13 [32] |
Proportion moving from ICHD - > home HD | Â | Â |
0 – 12 months | 0.05% (0.04% - 0.06%) | Assumption |
13 – 18 months | 0.03% (0.02% - 0.04%) |  |
19+ months | 0% | Â |
Proportion moving from home HD - > ICHD | Â | Â |
Constant probability | 0.38% (0.29% - 0.48%) | McFarlane [38] |
Proportion moving from HD - > PD | Â | Â |
0 – 6 months | Incident: 1.95% (1.46% - 2.44%) | |
| Â | Prevalent: 1.08% (0.81% - 1.35%) | Â |
7 – 12 months | 0.20% (0.15% - 0.25%) |  |
13 – 18 months | 0.07% (0.05% - 0.08%) |  |
19+ months | 0.06% (0.04% - 0.07%) | Â |
Proportion moving from PD - > HD | Â | Â |
0 – 6 months | Incident: 2.61% (1.96% - 3.26%) | |
| Â | Prevalent: 1.87% (1.40% - 2.34%) | Â |
7 – 12 months | 1.13% (0.85% - 1.41%) |  |
13 – 18 months | 0.78% (0.59% - 0.97%) |  |
19+ months | 0.31% (0.23% - 0.39%) | Â |